Renal Impairment Clinical Trial
Official title:
Evaluation of the Pharmacokinetics and Safety of Venetoclax in Subjects With Impaired Renal Function
Verified date | September 2022 |
Source | AbbVie |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Renal insufficiency is common in participants with blood cancers. The main objective of this study is to evaluate adverse events and movement of oral venetoclax tablets through the body of female participants with severe normal renal function and those with end stage renal disease (ESRD) requiring hemodialysis. Venetoclax is an investigational drug being developed for the treatment of various hematologic malignancies. Study doctors put the participants in 1 of 2 groups, called treatment arms. Each group receives a different treatment. Approximately 12 female participants between 18 and 75 years, with Body Mass Index (BMI) between 18 to 42 kg/m2 will be enrolled in approximately 4 sites across the world. Participants with normal renal function will receive single dose of oral venetoclax tablet. Participants with ESRD will receive oral venetoclax tablets just prior to hemodialysis (Period 1 Day 1) and between dialysis days (Period 2 Day 1), doses in the two periods will be separated by at least 7 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood and urine tests, checking for side effects.
Status | Completed |
Enrollment | 12 |
Est. completion date | August 16, 2022 |
Est. primary completion date | August 16, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Body mass index (BMI) between 18.0 and 42.0 kg/m2. - Postmenopausal or permanently surgically sterile (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy). - Women of childbearing potential, practicing at least 2 protocol specified methods of birth control that are effective from at least 30 days before starting study drug through at least 30 days after the last dose of any study drug. - Group 1 only: Must be in general good health based upon the results of a medical history, physical examination, and 12-lead electrocardiogram (ECG) with normal Glomerular Filtration Rate (GFR) at Screening. - Group 2 only: Stable condition and acceptable for study participation based upon the results of a medical history, physical examination, laboratory profile, and ECG. Participant with end stage renal disease (ESRD) requiring dialysis on hemodialysis must have been receiving hemodialysis for at least 1 month. Exclusion Criteria: - Participants on a strict vegetarian or vegan diet. |
Country | Name | City | State |
---|---|---|---|
United States | Acpru /Id# 243398 | Grayslake | Illinois |
United States | Orlando Clinical Research Ctr /ID# 224922 | Orlando | Florida |
Lead Sponsor | Collaborator |
---|---|
AbbVie | Roche-Genentech |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participants With Adverse Events (AEs) | An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study. A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above. | Up to approximately 38 days | |
Primary | Maximum Plasma Concentration (Cmax) of Venetoclax (Groups 1,2) | Maximum Plasma Concentration (Cmax) of Venetoclax. | Up to Day 6 | |
Primary | Time to Cmax (Tmax) of Venetoclax (Groups 1,2) | Time to Cmax (Tmax) of Venetoclax. | Up to Day 6 | |
Primary | Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48) of Venetoclax (Groups 1,2) | Area Under the Plasma Concentration-time Curve over time from time 0 to 48 hours (AUC0-48). | Up to Day 6 | |
Primary | Pre-dose Unbound Fraction (fu) of Venetoclax in Plasma (Groups 1,2) | Unbound Fraction (fu) of Venetoclax in Plasma. | Day 1 | |
Primary | Dialysis Clearance (CLdialysis) (Group 2) | Dialysis Clearance (CLdialysis) is calculated in participants undergoing hemodialysis in Period 1. | Day 1 | |
Primary | Unbound Fraction Pre-dialysis (fu,predialysis) of Venetoclax in Plasma (Group 2) | Unbound fraction pre-dialysis (fu,predialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1. | Day 1 | |
Primary | Unbound Fraction Post-dialysis (fu,postdialysis) of Venetoclax in Plasma (Group 2) | Unbound fraction post-dialysis (fu,postdialysis) of venetoclax in plasma is calculated in participants undergoing hemodialysis in Period 1. | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01937975 -
The Pharmacokinetics of Grazoprevir (MK-5172) and Elbasvir (MK-8742) in Participants With Renal Insufficiency (MK-5172-050)
|
Phase 1 | |
Completed |
NCT03284164 -
Evaluation of Effect of Renal Impairment on the PK of Tenofovir Exalidex
|
Phase 1 | |
Completed |
NCT05992155 -
A Study of TAK-279 in Adults With or Without Kidney Problems
|
Phase 1 | |
Completed |
NCT05004311 -
The Effect of Severe Kidney Impairment on Cenerimod Pharmacokinetics
|
Phase 1 | |
Completed |
NCT04963738 -
A Study of JNJ-73763989 in Adult Participants With Renal Impairment
|
Phase 1 | |
Terminated |
NCT02508740 -
Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment
|
Phase 1 | |
Active, not recruiting |
NCT01529658 -
Renal Hypothermia During Partial Nephrectomy
|
N/A | |
Terminated |
NCT00984113 -
Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT00750620 -
A Pharmacokinetic Study of YM178 in Normal Subjects and Those With Mild, Moderate, and Severe Renal Impairment
|
Phase 1 | |
Completed |
NCT00842868 -
The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
|
N/A | |
Completed |
NCT00499187 -
Fanconi Syndrome Due to ARVs in HIV-Infected Persons
|
Phase 4 | |
Completed |
NCT01331941 -
A Pharmacokinetic Study of AMG 386 in Cancer Subjects With Normal and Impaired Renal Function
|
Phase 1 | |
Completed |
NCT05489614 -
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Normal Renal Function and Participants With Various Degrees of Renal Impairment
|
Phase 1 | |
Completed |
NCT03259087 -
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
|
Phase 1 | |
Completed |
NCT05086107 -
Pharmacokinetics and Safety of BV100 Administered as Single Intravenous Infusion to Subjects With Renal Impairment
|
Phase 1 | |
Recruiting |
NCT05349851 -
Bowel Cleansing With Renal Impairment
|
||
Completed |
NCT03660241 -
A Renal Impairment Study for PF-04965842
|
Phase 1 | |
Recruiting |
NCT06037031 -
A Study to Learn How the Body Processes the Study Medicine Called PF-07923568 in People With Loss of Kidney Function
|
Phase 1 | |
Completed |
NCT03289208 -
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Renal Impairment
|
Phase 1 | |
Completed |
NCT02942810 -
To Investigate The Pharmacokinetics Of Intravenous WCK 5222 (FEP-ZID) In Patients With Renal Impairment
|
Phase 1 |